SELLAS Life Sciences (SLS) Notes Payables (2011)
SELLAS Life Sciences (SLS) reported Notes Payables of $500000.0 for Q4 2011, little changed quarter-over-quarter from $500000.0 in Q3 2011.
SELLAS Life Sciences (SLS) Notes Payables (2011) Analysis & Trends
SELLAS Life Sciences (SLS) has 1 years of Notes Payables data on file, last reported at $500000.0 in Q4 2011.
- Notes Payables for Q4 2011 came in at $500000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2011 was $500000.0 (changed N/A YoY), and the FY2011 annual result was $500000.0, changed N/A from the prior year.
- Notes Payables steadied at $500000.0 in Q4 2011 per SLS's latest filing, from $500000.0 in the prior quarter.
- Over five years, Notes Payables peaked at $500000.0 in Q3 2011 and troughed at $500000.0 in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 500,000.00 |
| Sep 30, 2011 | 500,000.00 |